Harrow, Inc.
HROW · Nasdaq · United States
Share price · HROW
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HROW's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+8.9%
Nothing announced by HROW that day or the session before.
- 13 Nov 2026+6.4%
- 10 Nov 2026+10.5%
- 10 Jun 2026+7.3%
- 12 May 2026-23.7%
- 3 Mar 2026-28.0%
- 2 Feb 2026+9.7%
- 9 Jan 2026-8.3%
Nothing announced by HROW that day or the session before.
- 5 Jan 2026+9.8%
Nothing announced by HROW that day or the session before.
- 12 Dec 2025-7.9%
Nothing announced by HROW that day or the session before.
Share of unusual movement by asset
For each asset, the share of HROW's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | VEGF-AProtein / enzyme therapeutic | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
| Approved | Voltage-gated sodium channels (Nav) on sensory nerve membranesSmall molecule | Ocular Anesthesia Ocular Surface Anesthesia | |
| Approved | CalcineurinSmall molecule | Dry Eye Disease | |
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration Wet Age-Related Macular Degeneration |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $99M | $10M | $75M | —-$8.6M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $71M | $8.1M | $84M | $17M-$9.8M operating cash flow | report ↗ |
| 2026-Q1 | $44M | $5.9M | $95M | $28M-$9.0M operating cash flow | report ↗ |
| 2025-Q3 | $72M | $3.3M | $74M | —$17M operating cash flow | report ↗ |
| 2025-Q2 | $64M | $2.9M | $53M | —-$0.8M operating cash flow | report ↗ |
| 2025-Q1 | $48M | $3.0M | $67M | $18M$20M operating cash flow | report ↗ |
| 2024-Q3 | $49M | $2.3M | $73M | $4.2M$3.0M operating cash flow | report ↗ |
| 2024-Q2 | $49M | $3.0M | $71M | $6.5M-$2.8M operating cash flow | report ↗ |
| 2024-Q1 | $35M | $2.1M | $69M+ $7.4M short-term inv. | $14M-$4.6M operating cash flow | report ↗ |
| 2023-Q3 | $34M | $1.4M | $66M+ $8.3M short-term inv. | $4.4M-$1.2M operating cash flow | report ↗ |
| 2023-Q2 | $33M | $1.2M | —+ $6.9M short-term inv. | $4.2M$4.6M operating cash flow | report ↗ |
| 2023-Q1 | $26M | $0.7M | —+ $7.6M short-term inv. | $6.6M-$8.2M operating cash flow | report ↗ |
| 2022-Q3 | $23M | $0.8M | $45M+ $4.2M short-term inv. | $6.5M-$0.4M operating cash flow | report ↗ |
| 2022-Q2 | $23M | $0.9M | $46M+ $5.2M short-term inv. | $6.2M$4.9M operating cash flow | report ↗ |
| 2022-Q1 | $22M | $0.7M | $42M+ $8.6M short-term inv. | $2.4M$1.0M operating cash flow | report ↗ |
| 2021-Q3 | $19M | $6.1M | $58M+ $10.0M short-term inv. | $8.3M-$2.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $272M | $21M | $73M | $1.3M$44M operating cash flow | report ↗ |
For the full year 2025, Harrow reported revenue of $272.3M, up 36.4% YoY, with R&D spend of $20.94M, up 71.2% YoY. Cash and equivalents stood at $72.93M, and the company recorded a net loss of $5.14M for the year.
The company issued 2026 revenue guidance of $350M to $365M, including $133M to $153M in the first half and $203M to $226M in the second half, alongside Adjusted EBITDA guidance of $80M to $100M. Harrow highlighted advancement of its development pipeline, including G-MELT, YOCHIL, and a next-generation TRIESENCE pre-filled syringe, and noted the 2025 acquisition of Melt Pharmaceuticals, which drove $8.5M of acquired in-process R&D expense. The company also generated $43.9M of operating cash flow in 2025 versus $(22.2)M used in 2024.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $200M | $12M | $47M | $4.4M-$22M operating cash flow | report ↗ |
| 2023-FY | $130M | $6.7M | $74M+ $8.7M short-term inv. | $6.1M$3.8M operating cash flow | report ↗ |
| 2022-FY | $89M | $3.0M | $96M+ $5.6M short-term inv. | $3.5M$1.7M operating cash flow | report ↗ |
| 2021-FY | $72M | $11M | $42M+ $8.5M short-term inv. | $4.5M$5.1M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($469K), 7 sales ($9.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-14 | Shojaei Amir · CHIEF SCIENTIFIC OFFICER | Option exercise | 11,250 | $35.96 | $405K | Form 4 |
| 2026-08-14 | Shojaei Amir · CHIEF SCIENTIFIC OFFICER | Open-market sale | 11,250 | $40.00 | $450K | Form 4 |
| 2026-08-14 | Shojaei Amir · CHIEF SCIENTIFIC OFFICER | Option exercise (derivative) | 11,250 | $35.96 | $405K | Form 4 |
| 2026-06-18 | Graves Adrienne L · director | Award / grant (derivative) | 5,248 | — | — | Form 4 |
| 2026-06-18 | SILVERNAIL LAUREN P · director | Award / grant (derivative) | 5,248 | — | — | Form 4 |
| 2026-06-18 | Sternberg Perry J. · director | Award / grant (derivative) | 5,248 | — | — | Form 4 |
| 2026-05-18 | SILVERNAIL LAUREN P · director | Open-market purchase | 1,000 | $31.00 | $31K | Form 4 |
| 2026-05-18 | Graves Adrienne L · director | Open-market purchase | 1,000 | $31.07 | $31K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 217 reporting institutions held 21.4M shares ($752.8M, 57.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Opaleye Management Inc. | 2,832,230 | $99.9M |
| 2 | BlackRock, Inc. | 2,552,759 | $90.0M |
| 3 | Private Capital Management, LLC | 1,562,000 | $55.1M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,403,056 | $49.5M |
| 5 | Luxor Capital Group, LP | 1,119,400 | $39.5M |
| 6 | STATE STREET CORP | 855,047 | $30.1M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 852,034 | $30.0M |
| 8 | MARSHALL WACE, LLP | 644,918 | $22.7M |
| 9 | DIMENSIONAL FUND ADVISORS LP | 579,520 | $20.4M |
| 10 | Ikarian Capital, LLC | 543,047 | $19.1M |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 457,782 | $16.1M |
| 12 | Penn Capital Management Company, LLC | 407,896 | $14.4M |
| 13 | RICE HALL JAMES & ASSOCIATES, LLC | 368,177 | $13.0M |
| 14 | GOLDMAN SACHS GROUP INC | 341,707 | $12.0M |
| 15 | NORTHERN TRUST CORP | 296,865 | $10.5M |